Speakers

*Speakers confirmed to-date.
Please check back as new speakers are being added

Co-Chairs

Stephanie Donahue

Principal Counsel, Patent Litigation
Sanofi- Aventis

Co-Chairs’ Opening Remarks

October 6, 2020 • 8:00 am

Pearl T. L. Siew

Senior Vice President and Head, Intellectual Property
Eagle Pharmaceuticals, Inc.

Co-Chairs’ Opening Remarks

October 6, 2020 • 8:00 am

United States District Court

Honorable Christopher J. Burke

Magistrate Judge
District of Delaware

Honorable Tonianne J. Bongiovanni

Magistrate Judge
District of New Jersey

Honorable Roy Payne

Magistrate Judge
Eastern District of Texas

Honorable Leonard P. Stark

Chief Judge
District of Delaware

And Now a Word from the District of Delaware: A Conversation with Chief Judge Stark and Chief Magistrate Judge Thynge

October 6, 2020 • 10:25 am

Honorable Mary Pat Thynge

Chief Magistrate Judge
District of Delaware

And Now a Word from the District of Delaware: A Conversation with Chief Judge Stark and Chief Magistrate Judge Thynge

October 6, 2020 • 10:25 am

U.S.P.T.O's Patent Trial and Appeal Board

Honorable Jacqueline Wright Bonilla

Vice Chief, Administrative Patent Judge

PTAB Stats and Substance: Questions and Controversies Surrounding Filings, Judicial Appointments, Standing, and Expanded Powers

October 6, 2020 • 5:00 pm

Honorable Michelle N. Ankenbrand

Lead Administrative Patent Judge

PTAB Stats and Substance: Questions and Controversies Surrounding Filings, Judicial Appointments, Standing, and Expanded Powers

October 6, 2020 • 5:00 pm

Honorable Kristi Rupert Sawert

Administrative Patent Judge

PTAB Stats and Substance: Questions and Controversies Surrounding Filings, Judicial Appointments, Standing, and Expanded Powers

October 6, 2020 • 5:00 pm

Government

Markus H. Meier

Assistant Director, Health Care Division, Bureau of Competition
U.S. Federal Trade Commission

FTC KEYNOTE: Antitrust Developments Impacting Brands and Generics

October 7, 2020 • 11:55 am

Grail Sipes

Deputy Center Director for Regulatory Policy, CDER

FDA Think Tank on the Latest Regulatory Developments Impacting Hatch-Waxman

October 7, 2020 • 1:15 pm

Maryll Toufanian

Director, Office of Generic Drug Policy, CDER
U.S. Food & Drug Administration

FDA Think Tank on the Latest Regulatory Developments Impacting Hatch-Waxman

October 7, 2020 • 1:15 pm

In-House Counsel

Karen E. Brown

Senior Vice President, Intellectual Property and Legal Affairs
Obsidian Therapeutics, Inc.

Examining How New and Narrow Interpretations of the Scope of Patent Term Extension Will Affect Patent Rights and Generic Entry

October 6, 2020 • 1:25 pm

Neal Dahiya

Assistant General Counsel – Patents
Bristol-Myers Squibb

Ryan M. Daniel

Chief Patent Counsel Region North America
Fresenius Kabi USA, LLC

The Continuing §101 Saga: Examining the Latest Patent Eligibility Developments in the Courts and at the PTO and How They are Influencing R&D, Claims Drafting, and Litigation Strategies

October 6, 2020 • 9:00 am

Stephanie Donahue

Principal Counsel, Patent Litigation
Sanofi- Aventis

Co-Chairs’ Opening Remarks

October 6, 2020 • 8:00 am

Henry Gu

Vice President, Chief IP Counsel
Akebia Therapeutics

Rekha Hanu, Ph.D, J.D

Executive Director, Chief IP Counsel
Akorn Pharmaceuticals

Donna Meuth

Associate General Counsel, IP
Eisai

New Studies in Obviousness: Thoughts on Inherency, Structure, Prior Art, and Secondary Considerations

October 7, 2020 • 2:45 pm

Mary Morry

Counsel
Merck & Company

The Doctrine of Equivalents: Analyzing the Effects of Recent Federal Circuit Decisions on ANDA Litigation Strategies

October 6, 2020 • 11:10 am

Brian Stone

Vice President Assistant Global General Counsel Regulatory
Mylan

FDA Think Tank on the Latest Regulatory Developments Impacting Hatch-Waxman

October 7, 2020 • 1:15 pm

Lars Taavola

VP, Chief Intellectual Property Counsel
Mallinckrodt Pharmaceuticals

Kevin Zive

Vice President – Global Intellectual Property and Legal Affairs
Apotex Inc.

Law Firms

Takanori Abe

Founder
Abe & Partners

David B. Abramowitz

Partner
Locke Lord LLP

Andrew J. Allen

Senior Director, Legal Counsel – IP
Dr. Reddy’s

John Bennett

Partner
Goodwin Procter LLP

Examining How New and Narrow Interpretations of the Scope of Patent Term Extension Will Affect Patent Rights and Generic Entry

October 6, 2020 • 1:25 pm

Aziz Burgy

Axinn, Veltrop & Harkrider LLP

Jonathan S. Caplan

Partner, Co-Chair, Intellectual Property
Kramer Levin Naftalis & Frankel LLP

Kathleen B. Carr

Member
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

New Studies in Obviousness: Thoughts on Inherency, Structure, Prior Art, and Secondary Considerations

October 7, 2020 • 2:45 pm

Alan B. Clement

Partner
Locke Lord LLP

David G. Conlin

Member
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

ETHICS DRILLS: Ethics and New Developments Impacting Professional Responsibility in the Hatch-Waxman Arena

October 7, 2020 • 3:45 pm

Evan Diamond

Partner
King & Spalding LLP

Paragraph IV State of the Union: Developing a New Game Plan for the New Normal: Assessing Legal, Regulatory, and Jurisprudential Developments in the Era of COVID-19

October 6, 2020 • 8:15 am

Gerald Flattmann

Partner
King & Spalding

Examining How New and Narrow Interpretations of the Scope of Patent Term Extension Will Affect Patent Rights and Generic Entry

October 6, 2020 • 1:25 pm

Jeffrey R. Gargano

Partner
Morgan, Lewis & Bockius LLP

The Continuing §101 Saga: Examining the Latest Patent Eligibility Developments in the Courts and at the PTO and How They are Influencing R&D, Claims Drafting, and Litigation Strategies

October 6, 2020 • 9:00 am

Vishal Gupta

Partner
Steptoe & Johnson LLP

Ryan Hagglund

Senior Counsel
Loeb & Loeb LLP

Paragraph IV State of the Union: Developing a New Game Plan for the New Normal: Assessing Legal, Regulatory, and Jurisprudential Developments in the Era of COVID-19

October 6, 2020 • 8:15 am

Staci Julie

SVP and Chief IP Counsel
Teva Pharmaceuticals

Kurt Karst

Director
Hyman, Phelps & McNamara PC

FDA Think Tank on the Latest Regulatory Developments Impacting Hatch-Waxman

October 7, 2020 • 1:15 pm

Pilar G. Kraman

Partner
Young Conaway Stargatt & Taylor, LLP

Chad Landmon

Partner
Axinn, Veltrop & Harkrider, LLP

Noah M. Leibowitz

Partner
Dechert LLP

William Marsillo

Partner
Boies, Schiller & Flexner LLP

Steven Maslowski

Partner
Akin Gump Strauss Hauer & Feld LLP

The Doctrine of Equivalents: Analyzing the Effects of Recent Federal Circuit Decisions on ANDA Litigation Strategies

October 6, 2020 • 11:10 am

John J. Molenda

Partner
Steptoe & Johnson LLP

Gregory A. Morris

Partner
Honigman LLP

PTAB Stats and Substance: Questions and Controversies Surrounding Filings, Judicial Appointments, Standing, and Expanded Powers

October 6, 2020 • 5:00 pm

Deepro R. Mukerjee

Partner & Member, Board of Directors; National Co- Chair, Patent Litigation
Katten Muchin Rosenman LLP

Sanjay K. Murthy

Partner
Morgan, Lewis & Bockius LLP

Huong Nguyen

General Counsel
Fosun Pharma USA Inc.

Examining How New and Narrow Interpretations of the Scope of Patent Term Extension Will Affect Patent Rights and Generic Entry

October 6, 2020 • 1:25 pm

Matthew Pearson

Partner
Akin Gump Strauss Hauer & Feld LLP

New Studies in Obviousness: Thoughts on Inherency, Structure, Prior Art, and Secondary Considerations

October 7, 2020 • 2:45 pm

Adam Perlman

Partner
Latham & Watkins LLP

The Doctrine of Equivalents: Analyzing the Effects of Recent Federal Circuit Decisions on ANDA Litigation Strategies

October 6, 2020 • 11:10 am

Stephen S. Rabinowitz

Partner
Dechert LLP

Colman Ragan

Vice President & General Counsel, North America IP
Teva Pharmaceuticals

Paragraph IV State of the Union: Developing a New Game Plan for the New Normal: Assessing Legal, Regulatory, and Jurisprudential Developments in the Era of COVID-19

October 6, 2020 • 8:15 am

Melanie R. Rupert

Partner and Co-Chair, Talent Development
Paul Hastings LLP

David Silverstein

Partner
Axinn, Veltrop & Harkrider LLP

Michael Sitzman

Partner
DLA Piper

The Doctrine of Equivalents: Analyzing the Effects of Recent Federal Circuit Decisions on ANDA Litigation Strategies

October 6, 2020 • 11:10 am

Jeanna M. Wacker

Partner
Kirkland & Ellis LLP

The Continuing §101 Saga: Examining the Latest Patent Eligibility Developments in the Courts and at the PTO and How They are Influencing R&D, Claims Drafting, and Litigation Strategies

October 6, 2020 • 9:00 am

Bruce M. Wexler

Partner and Global Co-Chair of IP
Paul Hastings LLP

Morning Roll Call with the District Judges

October 7, 2020 • 8:15 am